Stephens analyst Scott Fidel raised the firm’s price target on Addus HomeCare to $115 from $110 and keeps an Overweight rating on the shares. CMS released proposed Medicare Hospice provider rate updates for FY25 at +2.6%, reflecting a +$705M projected increase in overall payments, the analyst tells investors in a research note. The proposed FY25 rates compare to final and proposed FY2024 rates of +3.1% and +2.8%, respectively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Addus HomeCare price target raised to $115 from $108 at BofA
- Addus HomeCare initiated with an Equal Weight at Barclays
- Addus Homecare Unveils Year-End Financial Performance
- Addus HomeCare CEO ‘optimistic’ about acquisition opportunities in 2024
- Addus HomeCare reports Q4 adjusted EPS $1.32, consensus $1.17
